Core Scientific (CORZ) | Financial Analysis & Statements
Core Scientific Inc. Mid-cap Technology
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
79.8M
Gross Profit
20.8M
26.02%
Operating Income
-105.4M
-132.08%
Net Income
214.2M
268.48%
EPS (Diluted)
$0.42
Balance Sheet Metrics
Total Assets
2.3B
Total Liabilities
3.3B
Shareholders Equity
-962.7M
Cash Flow Metrics
Operating Cash Flow
495.8M
Free Cash Flow
-121.8M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Core Scientific Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 319.0M | 510.7M | 502.4M | 640.3M | 544.5M |
| Cost of Goods Sold | 281.1M | 389.6M | 378.9M | 631.9M | 305.6M |
| Gross Profit | 37.9M | 121.1M | 123.5M | 8.4M | 238.9M |
| Gross Margin % | 11.9% | 23.7% | 24.6% | 1.3% | 43.9% |
| Operating Expenses | |||||
| Research & Development | - | 11.8M | 7.2M | 27.0M | 7.7M |
| Selling, General & Administrative | 182.6M | 120.4M | 100.9M | 226.0M | 64.5M |
| Other Operating Expenses | 79.9M | 1.1M | - | - | - |
| Total Operating Expenses | 262.4M | 133.3M | 108.1M | 253.0M | 72.2M |
| Operating Income | -224.6M | -12.2M | 15.3M | -244.6M | 166.6M |
| Operating Margin % | -70.4% | -2.4% | 3.1% | -38.2% | 30.6% |
| Non-Operating Items | |||||
| Interest Income | 3.3M | - | - | - | - |
| Interest Expense | - | 37.1M | 86.2M | 96.8M | 44.4M |
| Other Non-Operating Income | -66.8M | -1.3B | -174.9M | -1.8B | -59.2M |
| Pre-tax Income | -288.0M | -1.3B | -245.8M | -2.2B | 63.1M |
| Income Tax | 583.0K | 859.0K | 683.0K | -17.1M | 15.8M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 25.0% |
| Net Income | -288.6M | -1.3B | -246.5M | -2.1B | 47.3M |
| Net Margin % | -90.5% | -257.5% | -49.1% | -335.2% | 8.7% |
| Key Metrics | |||||
| EBITDA | -77.6M | 108.2M | 114.3M | -210.6M | 184.0M |
| EPS (Basic) | $-0.88 | $-4.39 | $-0.65 | $-6.30 | $0.15 |
| EPS (Diluted) | $-0.88 | $-4.39 | $-0.65 | $-6.30 | $0.15 |
| Basic Shares Outstanding | 318068000 | 255832000 | 379863000 | 340647000 | 317279900 |
| Diluted Shares Outstanding | 318068000 | 255832000 | 379863000 | 340647000 | 317279900 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Core Scientific Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 311.4M | 836.2M | 50.4M | 15.9M | 117.9M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 337.2M | 1.0M | 1.0M | 257.0K | 1.7M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 247.0M | 66.0M | 5.3M | 1.0M | 236.5M |
| Total Current Assets | 895.5M | 904.0M | 97.0M | 85.1M | 756.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 599.5M | 614.1M | 517.0M | 536.5M | 60.4M |
| Goodwill | - | - | 2.2M | 1.7M | 2.1B |
| Intangible Assets | - | - | - | 1.7M | 8.2M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 48.5M | 24.0M | 19.6M | 9.3M | 12.0M |
| Total Non-Current Assets | 1.5B | 694.9M | 615.1M | 722.6M | 1.7B |
| Total Assets | 2.3B | 1.6B | 712.2M | 807.7M | 2.4B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 126.1M | 19.3M | 154.8M | 53.6M | 11.6M |
| Short-term Debt | 12.3M | 27.9M | 144.2M | 37.0M | 104.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 3.4M | 17.6M | 6.8M | 1.6M | 4.4M |
| Total Current Liabilities | 781.4M | 134.6M | 488.4M | 186.8M | 320.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.2B | 1.2B | 721.3M | 720.0K | 714.4M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 14.4M | 15.3M | 99.3M | 1.0B | 18.5M |
| Total Non-Current Liabilities | 2.5B | 2.3B | 820.7M | 1.0B | 777.4M |
| Total Liabilities | 3.3B | 2.4B | 1.3B | 1.2B | 1.1B |
| Equity | |||||
| Common Stock | 3.0K | 3.0K | 36.0K | 36.0K | 27.0K |
| Retained Earnings | -4.1B | -3.7B | -2.4B | -2.2B | -27.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -962.7M | -820.2M | -596.9M | -409.3M | 1.3B |
| Key Metrics | |||||
| Total Debt | 1.2B | 1.2B | 865.5M | 37.7M | 818.8M |
| Working Capital | 114.1M | 769.4M | -391.4M | -101.7M | 436.3M |
Balance Sheet Composition
Core Scientific Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -288.6M | -1.3B | -246.5M | -2.1B | 47.3M |
| Depreciation & Amortization | 80.2M | 120.1M | 96.4M | 226.1M | 33.4M |
| Stock-Based Compensation | 98.2M | 51.9M | 58.9M | 182.9M | 38.9M |
| Working Capital Changes | 525.7M | -9.1M | 441.4M | 359.4M | 172.8M |
| Operating Cash Flow | 222.5M | -1.4B | -30.8M | -1.8B | 120.2M |
| Investing Activities | |||||
| Capital Expenditures | -725.5M | -95.0M | -2.2M | -601.7M | 704.0K |
| Acquisitions | -5.0M | 0 | 0 | 0 | -365.2M |
| Investment Purchases | - | - | - | - | -59.3M |
| Investment Sales | - | - | 0 | 10.8M | - |
| Investing Cash Flow | -730.5M | -95.0M | -2.2M | -590.8M | -423.8M |
| Financing Activities | |||||
| Share Repurchases | - | 0 | 0 | -31.6M | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 1.1B | 0 | 261.3M | 670.8M |
| Debt Repayment | -10.3M | -310.9M | -44.6M | -143.6M | -57.0M |
| Financing Cash Flow | -70.0M | 814.7M | -44.6M | 281.1M | 957.4M |
| Free Cash Flow | -461.0M | -52.3M | 48.1M | -396.5M | -56.7M |
| Net Change in Cash | -578.1M | -672.5M | -77.6M | -2.1B | 653.8M |
Cash Flow Trend
Core Scientific Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-23.64
Forward P/E
50.61
Price to Book
-6.90
Price to Sales
21.03
PEG Ratio
0.12
Profitability Ratios
Profit Margin
-90.47%
Operating Margin
-78.49%
Return on Equity
29.98%
Return on Assets
-5.76%
Financial Health
Current Ratio
1.15
Debt to Equity
-1.21
Beta
6.36
Per Share Data
EPS (TTM)
$-0.88
Book Value per Share
$-3.06
Revenue per Share
$1.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CORZ | 6.6B | -23.64 | -6.90 | 29.98% | -90.47% | -1.21 |
| Microsoft | 3.1T | 26.56 | 8.06 | 34.39% | 39.04% | 31.54 |
| Oracle | 498.4B | 31.65 | 15.11 | 57.57% | 25.30% | 415.27 |
| DigitalOcean | 9.9B | 37.78 | -304.26 | -903.67% | 28.76% | -59.30 |
| Nutanix | 9.3B | 37.40 | -11.11 | -27.12% | 9.95% | -1.86 |
| Informatica | 7.6B | 826.33 | 3.12 | 0.43% | 0.62% | 75.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.






